Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure

(2013) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis

(2013) K. Damman et al.   EUROPEAN HEART JOURNAL

The role of the kidney in heart failure

(2012) M. Metra et al.   EUROPEAN HEART JOURNAL

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

(2012) Marco Metra et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

(2012) John R Teerlink et al.   LANCET

Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function

(2011) Kevin Damman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Circadian Clock in the Kidney

(2011) L. R. Stow et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality

(2010) Kevin Damman et al.   EUROPEAN JOURNAL OF HEART FAILURE

Intravenous Recombinant Human Relaxin in Compensated Heart Failure: A Safety, Tolerability, and Pharmacodynamic Trial

(2009) Thomas Dschietzig et al.   JOURNAL OF CARDIAC FAILURE

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study

(2009) John R Teerlink et al.   LANCET

Differential associations between renal function and “modifiable” risk factors in patients with chronic heart failure

(2008) Tom D. J. Smilde et al.   Clinical Research in Cardiology